Is the Medication Right for Me? Does It Interact With My Other Medications?

Who Qualifies for a GLP-1 Receptor Agonist?

FDA approval criteria set the starting point for any candidacy discussion. Semaglutide 2.4 mg (Wegovy) carries an indication for adults with a BMI of 30 kg/m² or above, or a BMI of 27 kg/m² or above plus at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia [1]. Tirzepatide 15 mg (Zepbound) shares the same BMI thresholds under its 2023 FDA approval [2].

Body Weight Is Only One Variable

Meeting the BMI cutoff does not automatically mean a GLP-1 agonist is the best option for you. Your prescriber will also look at cardiovascular history, kidney function, and whether you have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2). Both semaglutide and liraglutide carry FDA black-box warnings for this thyroid-tumor risk, based on rodent data, and are contraindicated in anyone with that history [3].

Metabolic Conditions That Favor Prescribing

Certain diagnoses move the needle toward a prescription more strongly. In the SELECT trial (N=17,604), semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% compared with placebo in adults with overweight or obesity and established cardiovascular disease, regardless of whether they had diabetes [4]. Patients who carry cardiovascular risk therefore have an evidence-based reason to discuss a GLP-1 with their cardiologist or internist, not just their weight-management physician.

Type 2 diabetes adds another layer of evidence. The SUSTAIN-6 trial (N=3,297) showed semaglutide 0.5 mg and 1.0 mg reduced the composite cardiovascular endpoint by 26% versus placebo (HR 0.74; 95% CI 0.58 to 0.95; P<0.001) [5].

Absolute Contraindications You Must Discuss With Your Prescriber

Some situations make GLP-1 agonists medically inappropriate, regardless of your BMI or metabolic profile.

Thyroid Cancer History

All GLP-1 receptor agonists in the semaglutide and liraglutide class are contraindicated in patients with a personal or family history of MTC, or in patients with MEN2 [3]. Your prescriber will ask about this directly during intake. Calcitonin monitoring may be relevant if your history is uncertain.

Pregnancy and Breastfeeding

Pregnancy is an absolute contraindication for every approved GLP-1 agonist. The FDA prescribing information for semaglutide (Wegovy) explicitly states to discontinue the drug at least two months before a planned pregnancy [3]. Animal studies have shown fetal harm at doses below human therapeutic exposure levels. Women of reproductive potential should use reliable contraception and notify their prescriber immediately if pregnancy occurs during treatment.

Pancreatitis History

A personal history of pancreatitis, whether acute or chronic, is a reason for caution and possibly for avoiding GLP-1 agents entirely. The FDA label for semaglutide includes pancreatitis as a warning, and prescribers are advised to discontinue the drug if pancreatitis is suspected [3]. Post-marketing data do not confirm a definitive causal link, but the mechanistic plausibility is sufficient to make prior pancreatitis a contraindication in most clinical protocols.

Severe Gastroparesis

Because GLP-1 agonists slow gastric emptying significantly, patients with confirmed gastroparesis or severe gastroesophageal reflux disease should discuss this with their prescriber before starting. The gastric-slowing effect can worsen pre-existing motility disorders and complicate glucose management in people who rely on predictable nutrient absorption [6].

How GLP-1 Agents Interact With Other Medications

This is the section most patients underestimate. GLP-1 receptor agonists do not inhibit cytochrome P450 enzymes directly, but they alter drug pharmacokinetics through gastric emptying delay and, in some cases, changes in body weight and volume of distribution.

Oral Medications With Narrow Therapeutic Windows

The gastric-emptying slowdown produced by semaglutide and liraglutide can meaningfully reduce or delay the peak plasma concentration of drugs that depend on rapid absorption. Oral contraceptives are a notable example. The FDA label for semaglutide advises switching to a non-oral contraceptive method or adding a barrier method for 4 weeks after each dose escalation [3]. Levothyroxine absorption may also change, and thyroid-stimulating hormone (TSH) should be rechecked 6 to 8 weeks after starting or escalating a GLP-1 agonist in anyone on thyroid replacement therapy.

Cyclosporine, tacrolimus, and other immunosuppressants with narrow therapeutic windows require close monitoring because even a modest shift in absorption timing can push a patient outside the therapeutic range.

Insulin and Sulfonylureas

The highest-priority interaction for safety is the combination of a GLP-1 agonist with insulin or a sulfonylurea such as glipizide or glibenclamide. GLP-1 agents lower blood glucose through glucose-dependent insulin release. Stacking them with drugs that release insulin in a glucose-independent manner raises hypoglycemia risk substantially [7]. The American Diabetes Association 2024 Standards of Care recommend reducing insulin or sulfonylurea doses by 20 to 50% when initiating a GLP-1 agonist, with glucose monitoring during the titration period [7].

Metformin

Metformin and GLP-1 agonists are frequently prescribed together and are generally safe in combination. The two drugs work through different mechanisms. Metformin primarily reduces hepatic glucose output, while GLP-1 agonists stimulate glucose-dependent insulin secretion and slow gastric emptying. No dose adjustment for metformin is required when a GLP-1 agonist is added, provided renal function is adequate [7].

Blood Pressure Medications

GLP-1 agonists produce modest blood pressure reductions, typically 2 to 5 mmHg systolic, as a secondary effect [8]. Patients who are already well-controlled on antihypertensive therapy may need dose reductions after sustained weight loss of 10% or more. This is not a drug-drug interaction in the pharmacokinetic sense, but it is a clinically relevant pharmacodynamic interaction that requires monitoring.

Anticoagulants

Warfarin requires special attention. Because GLP-1-induced weight loss changes body composition, volume of distribution, and dietary patterns (particularly vitamin K intake), INR can drift unpredictably. Patients on warfarin should have INR checked more frequently during the first three months of GLP-1 therapy and after any dose escalation. Direct oral anticoagulants such as apixaban and rivaroxaban are absorbed differently from warfarin and carry lower interaction risk, but your prescriber should still be aware of any anticoagulant you are taking.

Kidney Disease and Hepatic Impairment

Renal Function Considerations

Semaglutide (both oral and injectable) does not require dose adjustment for renal impairment at any stage, according to FDA labeling [3]. Liraglutide is generally not recommended in severe renal impairment (eGFR <30 mL/min/1.73 m²) because limited safety data exist for that population. Tirzepatide similarly carries no required renal dose adjustment per its 2023 FDA label, but post-marketing surveillance in stage 4 and 5 CKD patients is still accumulating [2].

Nausea and vomiting from GLP-1 initiation can cause dehydration and transiently worsen renal function. Prescribers often recommend temporarily holding nephrotoxic medications such as NSAIDs during dose escalation in patients with baseline CKD.

Hepatic Impairment

Mild-to-moderate hepatic impairment does not appear to alter semaglutide exposure significantly. Severe hepatic impairment data are limited, and prescribers typically proceed with caution or avoid GLP-1 agents when Child-Pugh class C cirrhosis is present [3].

Mental Health Medications and Neuropsychiatric Considerations

Several medications used for depression, bipolar disorder, and psychosis are associated with weight gain. Olanzapine, quetiapine, and lithium are among the most weight-promoting psychiatric drugs. Adding a GLP-1 agonist to offset medication-induced weight gain is an active clinical research area and is used off-label in some psychiatric practices.

The FDA added a label update in 2024 noting that suicidal ideation reports had been submitted for GLP-1 agonists, but a review by the agency did not establish a causal relationship [9]. Prescribers should nonetheless document baseline mood and ask about psychiatric history before starting therapy, particularly in patients on mood-stabilizing or antidepressant regimens.

A Practical Medication Review Framework

Before your first appointment, gather the following for your prescriber:

• A complete medication list including dose and frequency for every prescription drug, over-the-counter product, and supplement.
• The name of the pharmacy you use, so the prescriber can run a database interaction check.
• Your most recent labs: comprehensive metabolic panel, lipid panel, HbA1c, TSH, and CBC, ideally within the past 6 months.
• Any history of pancreatitis, thyroid cancer, or eating disorder (anorexia nervosa and bulimia are relative contraindications because of the appetite-suppression mechanism).
• Your contraception method if you are of reproductive potential.

Bringing this information to your intake appointment cuts prescriber review time substantially and reduces the chance of a delay caused by missing safety information.

Oral Semaglutide and the Absorption Problem

Rybelsus (oral semaglutide) introduces a pharmacokinetic complexity that the injectable form does not have. Oral semaglutide must be taken on an empty stomach with no more than 4 oz of plain water and requires a 30-minute fast before eating or taking other medications [3]. This requirement means any other morning medication you take on an empty stomach, such as levothyroxine or bisphosphonates, will need timing adjustment. Patients on multiple fasted morning medications should discuss a sequencing schedule with their pharmacist and prescriber before starting oral semaglutide.

Supplements and Over-the-Counter Products

Berberine

Berberine has documented glucose-lowering effects through AMPK activation and may add to the hypoglycemic burden of GLP-1 therapy in patients already on insulin or a sulfonylurea. Although berberine is available without a prescription, it should be disclosed to your prescriber as part of your full medication list [10].

High-Dose Fish Oil

Omega-3 fatty acids at prescription doses (icosapentaenoic acid 4 g/day as in Vascepa) are sometimes co-prescribed for hypertriglyceridemia. GLP-1 agonists also lower triglycerides by roughly 12 to 26% in clinical trials [8]. The combination is not contraindicated, but triglyceride levels should be monitored to guide dosing of both agents.

St. John's Wort

St. John's Wort is a potent CYP3A4 inducer and will reduce plasma levels of many co-administered drugs. While it does not interact directly with GLP-1 receptor pharmacology, patients taking St. John's Wort alongside oral contraceptives, cyclosporine, or certain antiretrovirals may see those drugs lose efficacy. This is a relevant concern if GLP-1 therapy is being added to an already-complex regimen.

How Your Prescriber Makes the Final Decision

The decision tree a clinician uses is roughly as follows. First, they confirm eligibility using BMI and comorbidity criteria per FDA labeling. Second, they screen for absolute contraindications (MTC/MEN2 history, pregnancy, active pancreatitis). Third, they review your full medication list with a focus on oral drugs with narrow therapeutic windows, insulin and sulfonylurea combinations, and anticoagulants. Fourth, they order or review baseline labs. Fifth, they document a shared-decision-making conversation that covers expected benefits, common side effects (nausea in 40 to 44% of patients during titration in STEP-1 [11]), and the monitoring plan.

The Endocrine Society 2023 Clinical Practice Guideline on obesity pharmacotherapy states: "We recommend pharmacotherapy as an adjunct to lifestyle intervention in patients who do not achieve clinically meaningful weight loss with lifestyle alone and who meet BMI eligibility criteria, after evaluation for contraindications and drug interactions" [12].

The American Diabetes Association 2024 Standards of Care similarly states: "In adults with type 2 diabetes and established cardiovascular disease, heart failure, or chronic kidney disease, a GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit is recommended as part of the glucose-lowering regimen, independent of HbA1c" [7].

What to Do If You Take Many Medications

Polypharmacy, defined as taking five or more medications concurrently, affects roughly 42% of U.S. Adults aged 65 and older [13]. If you fall into this group, a few steps reduce your risk.

Ask for a pharmacist-led medication review before your GLP-1 prescriber appointment. Clinical pharmacists are trained specifically in drug-drug interaction screening and can flag problems your primary care physician may not have time to identify. The ACCP (American College of Clinical Pharmacy) supports pharmacist involvement in GLP-1 initiation workflows for high-risk patients.

Request dose-titration monitoring. Because drug interactions with GLP-1 agents often surface during dose escalation rather than at the starting dose, plan for a follow-up lab or telehealth check at weeks 4, 8, and 16 of therapy, at minimum.

Do not stop any existing medication without prescriber guidance. GLP-1-induced nausea sometimes leads patients to stop other oral medications during the initiation phase because they are already taking less by mouth. Stopping blood pressure medications, anticoagulants, or antiseizure drugs abruptly carries its own risks.

Special Populations

Adults Over 65

Older adults have higher rates of polypharmacy, reduced renal clearance, and a greater risk of dehydration-related acute kidney injury from GLP-1-associated nausea and vomiting. The STEP-4 trial included participants up to age 75, and the safety profile was broadly consistent with younger adults, though GI adverse events trended slightly higher in the older subgroup [14]. Prescribers often use slower titration schedules in patients over 65.

Adolescents Ages 12 to 17

Semaglutide 2.4 mg received FDA approval for adolescents aged 12 and older with a BMI at or above the 95th percentile in December 2022 [1]. Drug interactions in this population follow the same pharmacological principles as adults, but prescribers must also consider potential effects on bone mineral density, pubertal development, and the interaction with any stimulant medications used for ADHD, which can independently affect appetite and weight.